TLPH Share Price Performance
US$0
-0.51 (-100.00%)
Price US$0
Fair ValueUS$3.25
Share Pricen/a
Talphera, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
TLPH Community Narratives
AN
Fair Value
·Fair Value US$3.25 74.8% undervalued intrinsic discount
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
Catalysts About Talphera Talphera is a clinical stage biopharmaceutical company developing Niyad, a regional anticoagulant designed for use in continuous renal replacement therapy. What are the underlying business or industry changes driving this perspective?Read more
AN
US$3.25
74.8% undervalued intrinsic discount
Fair Value
Profit Margin
20.88%
Future PE
64.25x
Price in 2028
US$3.98
Trending Discussion
Recently Updated Narratives
AN
Regional Anticoagulant Adoption Will Drive Long Term Opportunity In Renal Replacement Therapy
Fair Value: US$3.25 74.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Talphera, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.27
- -24,500.00%
- -1,425,300.00%
- 35.2%
About TLPH
- Founded
- 2005
- Employees
- 12
- CEO
- WebsiteView website
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
